SCHEMBL257089

SCHEMBL257089

CCOc1cccc(CC)c1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.61
GABRB2 P47870 1/20 0.61
L3MBTL1 Q9Y468 3/20 0.56
MAPT P10636 3/20 0.56
NPSR1 Q6W5P4 2/20 0.56
GLA P06280 1/20 0.47
GAA P10253 3/20 0.47
LMNA P02545 1/20 0.47
XBP1 P17861 1/20 0.47
HSD17B10 Q99714 1/20 0.47
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
THRB P10828 1/20 0.46
RECQL P46063 1/20 0.46
BLM P54132 1/20 0.46
ATM Q13315 1/20 0.46
PLEC Q15149 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ALOX5 P09917 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30940116 0.86 ALDH1A1 (0.46) GABRA1GABRB2L3MBTL1MAPTNPSR1
SCHEMBL9825698 0.85 ALDH1A1 (0.52) L3MBTL1MAPTNPSR1GLAGAA
SCHEMBL674008 0.85 ALDH1A1 (0.52) L3MBTL1MAPTNPSR1GLAGAA
SCHEMBL11723222 0.85 MAPT (0.44) GABRA1GABRB2L3MBTL1MAPTNPSR1
SCHEMBL6819447 0.85 ALDH1A1 (0.46) GABRA1GABRB2L3MBTL1MAPTNPSR1
SCHEMBL11387620 0.85 ALOX5 (0.56) GABRA1GABRB2L3MBTL1MAPTNPSR1
SCHEMBL11504710 0.85 GABRA1 (0.57) GABRA1GABRB2L3MBTL1MAPTNPSR1
SCHEMBL5120093 0.84 L3MBTL1 (0.53) GABRA1GABRB2L3MBTL1MAPTNPSR1
SCHEMBL921504 0.83 GABRA1 (0.67) GABRA1GABRB2L3MBTL1MAPTNPSR1
SCHEMBL16534556 0.83 IDO1 (0.51) GABRA1GABRB2L3MBTL1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2760815-B1 METHOD FOR PRODUCING ALKOXY-HYDROXYBENZALDEHYDE THAT IS SUBSTANTIALLY FREE OF ALKYL-ALKOXY-HYDROXYBENZALDEHYDE RHODIA OPERATIONS (FR) 2016-08-24 EP claimed
EP-2760815-A1 METHOD FOR PRODUCING ALKOXY-HYDROXYBENZALDEHYDE THAT IS SUBSTANTIALLY FREE OF ALKYL-ALKOXY-HYDROXYBENZALDEHYDE RHODIA OPERATIONS (FR) 2014-08-06 EP claimed
WO-2014016145-A1 METHOD FOR PRODUCING ALKOXY-HYDROXYBENZALDEHYDE THAT IS SUBSTANTIALLY FREE OF ALKYL-ALKOXY-HYDROXYBENZALDEHYDE RHODIA OPERATIONS (FR) 2014-01-30 WO claimed
US-9650322-B2 Method for producing alkoxyhydroxybenzaldehyde RHODIA OPERATIONS (FR) 2017-05-16 US disclosed
US-20160251291-A1 METHOD FOR PRODUCING ALKOXYHYDROXYBENZALDEHYDE RHODIA OPERATIONS (FR) 2016-09-01 US disclosed
EP-2760815-B1 METHOD FOR PRODUCING ALKOXY-HYDROXYBENZALDEHYDE THAT IS SUBSTANTIALLY FREE OF ALKYL-ALKOXY-HYDROXYBENZALDEHYDE RHODIA OPERATIONS (FR) 2016-08-24 EP disclosed
US-9284247-B2 Method for producing alkoxy-hydroxybenzaldehyde that is substantially free of alkyl-alkoxy-hydroxybenzaldehyde RHODIA OPERATIONS (FR) 2016-03-15 US disclosed
US-20150203428-A1 Method for producing alkoxy-hydroxybenzaldehyde that is substantially free of alkyl-alkoxy-hydroxybenzaldehyde SPECIALTY OPERATIONS FRANCE (FR) 2015-07-23 US disclosed
EP-2760815-A1 METHOD FOR PRODUCING ALKOXY-HYDROXYBENZALDEHYDE THAT IS SUBSTANTIALLY FREE OF ALKYL-ALKOXY-HYDROXYBENZALDEHYDE RHODIA OPERATIONS (FR) 2014-08-06 EP disclosed
WO-2014016145-A1 METHOD FOR PRODUCING ALKOXY-HYDROXYBENZALDEHYDE THAT IS SUBSTANTIALLY FREE OF ALKYL-ALKOXY-HYDROXYBENZALDEHYDE RHODIA OPERATIONS (FR) 2014-01-30 WO disclosed
WO-2012028578-A1 SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES BAYER CROPSCIENCE AG (DE) 2012-03-08 WO disclosed
US-7517875-B2 Piperidine derivatives having CCR3 antagonism TEIJIN LIMITED (JP) 2009-04-14 US disclosed
US-7271270-B2 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION (US) 2007-09-18 US disclosed
US-20070037851-A1 Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) 2007-02-15 US disclosed
US-20070032525-A1 Piperidine derivatives having ccr3 antagonism TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) 2007-02-08 US disclosed
EP-0287675-B1 PROCESS FOR PRODUCING BIPHENOLS MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1992-01-02 EP disclosed
US-4902837-A OXIDATION COUPLING OF PHENOLS MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1990-02-20 US disclosed
EP-0287675-A1 PROCESS FOR PRODUCING BIPHENOLS MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1988-10-26 EP disclosed
US-4272550-A Omega-[4-(polyfluoro-2-hydroxy-2-propyl)-2,3,6-substituted-phenoxy and phenylthio]alkanoic acids and compounds related thereto SCHERING CORPORATION (US) 1981-06-09 US disclosed
US-4199597-A Omega-(4-polyfluoro-2-hydroxy-2-propyl)-2,3,6-substituted-phenoxy and phenylthio)alkanoic acids and compounds related thereto SCHERING CORPORATION (US) 1980-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203428-A1 Method for producing alkoxy-hydroxybenzaldehyde that is substantially free of alkyl-alkoxy-hydroxybenzaldehyde HPD, APEH, HMBS GABRA1 2102/4885GABRB2 1052/4885L3MBTL1 2256/4885
US-20070032525-A1 Piperidine derivatives having ccr3 antagonism CCR3, CCR1, CCR4 GABRA1 1141/4885GABRB2 2290/4885L3MBTL1 3446/4885
US-20070037851-A1 Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells CCR3, CCR1, CCR4 GABRA1 933/4885GABRB2 1739/4885L3MBTL1 3593/4885
US-20160251291-A1 METHOD FOR PRODUCING ALKOXYHYDROXYBENZALDEHYDE ALKBH3, OGG1, GRHPR GABRA1 2696/4885GABRB2 2457/4885L3MBTL1 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.